ClinicalTrials.gg
CompletedNCT04785677Updated Aug 28, 2026Results posted

Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration

An interventional study of Resiliency in Stressful Experiences (RISE) Program in Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute and Depressive Symptoms, sponsored by Florida State University. Completed at 1 site in United States. Open to male participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Primary conditionStress Disorders, Traumatic, AcuteRegistry: Stress Disorders, TraumaticReclassifiedWhy we changed it
Registry
Stress Disorders, Traumatic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stress Disorders, Traumatic, Acute
Why
  1. The study's listed conditions name Stress Disorders, Traumatic, Acute, a narrower term within Stress Disorders, Traumatic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Florida State University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

The investigators are conducting a randomized controlled trial to assess the impact of Resiliency in Stressful Experiences (RISE) - a comprehensive trauma-based program for young men releasing from a southeastern state's prisons. The investigators are assessing whether treating trauma and providing other transitional supports - such as employment assistance - as young men return home will help to improve their community stability and enhance their psychological well-being, in turn, resulting in less likelihood that a person will become incarcerated in the future.

Read the detailed description

The five-year study is a two-armed, randomized controlled trial evaluating the effectiveness of a comprehensive trauma-based reentry program for young men assessed as moderate to high risk for recidivism as they are released to the community. Four Hundred young males who were released from one of ten Florida prisons into our target counties were randomly assigned to receive a comprehensive trauma-based reentry program or treatment as usual. The effectiveness of the reentry program was evaluated on mechanisms of change (trauma symptoms, coping, impulsivity, and aggression), community stability (housing, employment), and recidivism.

Research questions are: Does a comprehensive trauma-based research program improve key mechanisms of change for moderate to high-risk young males? Does a comprehensive trauma-based reentry program improve community stability for moderate to high-risk young males? Does a comprehensive trauma-based reentry program decrease rates of recidivism for moderate to high-risk young males? Research questions 1 and 2 were analyzed using ANCOVA, and Research Question 3 will be analyzed using survival analysis. We also used a Research-to-Practice Feedback Loop to catalyze rapid assessment of intervention and implementation refinement to increase participant responsivity.

02

Conditions studied

  • Stress Disorders, Traumatic
  • Stress Disorders, Traumatic, Acute
  • Depressive Symptoms
  • Anxiety
  • Substance Use
  • Aggression
  • Coping Skills
  • Impulsive Behavior
  • Housing Problems
  • Recidivism
  • Stress
  • Occupational Stress
  • Psychological Distress

Keywords

  • employment stability
  • Housing Stability
  • Reentry
  • Trauma
  • psychological wel-being
03

In context

Stress Disorders, Traumatic, Acute Reclassified

58 studies on the registry are indexed under Stress Disorders, Traumatic, Acute; 15 are open to participants now.

This study's enrollment of 403 is above the median of 91 across 52 interventional studies indexed under Stress Disorders, Traumatic, Acute.

Browse Stress Disorders, Traumatic, Acute studies →

Lead sponsor

Florida State University is the lead sponsor of 249 studies on the registry; 47 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Compared within Stress Disorders, Traumatic, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stress Disorders, Traumatic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males
  • Ages 18-35
  • Have experienced at least one lifetime traumatic event
  • Released from incarceration to Suwanee, Leon, Duval or Columbia County, Florida.
  • Conversational in English
  • Being able to cognitively consent

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old
  • Older than 35 years old
  • Has not experienced at least one lifetime traumatic event
  • Not cognitively able to understand
  • Not conversational in English
  • Not releasing from incarceration to Suwanee, Leon, Duval or Columbia County, Florida.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Comprehensive Trauma-Based Reentry Program

    Participants will complete up to19 session comprehensive trauma-based reentry program.

    Behavioral: Resiliency in Stressful Experiences (RISE) Program

  • No intervention
    Treatment as usual (TAU)

    Participants will be receive all reentry services normally eligible to receive by the state or the community to which they are released.

Interventions

  • BehavioralResiliency in Stressful Experiences (RISE) Program

    The Resiliency in Stressful Experiences (RISE) Program is a multi-phased comprehensive trauma based reentry program designed based on the transitional nature of reentry. Participants will receive up to 4 sessions prior to release and up tp 15 session post release from prison. The RISE program is a trauma intervention paired with reentry services, including housing support and employment assistance.

    Also known as: Comprehensive Trauma-Based Reentry Program

06

What researchers measure

Primary outcomes

  1. Housing Stability

    Stable housing was defined as living in one's own room, apartment, or house, or with family, with an expected duration of residence of 4 months or more, or tenancy rights. A 10- item measure will assess housing stability.

    Time frame: 4 months post release

  2. Housing Stability

    Stable housing was defined as living in one's own room, apartment, or house, or with family, with an expected duration of residence of 4 months or more, or tenancy rights. A 10- item measure will assess housing stability.

    Time frame: 8 months post release

  3. Employment Stability

    Employment Stability is measure on a continuum, based on the number of jobs held in the last 4 months and number of days worked at each Employment. The employment must be for at least 15 hours a week. A 10-item measure will assess employment stability

    Time frame: 4 months post release

  4. Employment Stability

    Employment Stability is based on the number of jobs held in the last 4 months and number of days worked at each Employment. The employment must be for at least 15 hours a week. A 10-item measure will assess employment stability

    Time frame: 8 months post release

  5. Brief Symptom Inventory

    Utilizing the Brief Symptom Inventory (BSI) to assess depression and anxiety symptoms in participants. The BSI is a 53-item self-report screening tool that asks respondents to rate their level of psychological distress over the past seven days based on a five-point Likert scale (0 = "not at all" to 5 = "extremely"). The BSI provides subscale scores on dimensions of somatization, depression, and anxiety as well as a Global Severity Index (GSI) that is calculated based on a sum of all items. Subscale scores range from 0 to 4. Higher scores on the BSI indicate higher levels of symptomology.

    Time frame: 4 months post release

  6. Brief Symptom Inventory

    Utilizing the Brief Symptom Inventory (BSI) to assess depression and anxiety symptoms in participants. The BSI is a 53-item self-report screening tool that asks respondents to rate their level of psychological distress over the past seven days based on a five-point Likert scale (0 = "not at all" to 5 = "extremely"). The BSI provides subscale scores on dimensions of somatization, depression, and anxiety as well as a Global Severity Index (GSI) that is calculated based on a sum of all items. Subscale scores range from 0 to 4. Higher scores on the BSI indicate higher levels of symptomology.

    Time frame: 8 months post release

  7. Mini International Neuropsychiatric Interview

    Utilizing the 9-item substance use disorder subscale of the MINI International Neuropsychiatric Interview (MINI) to assess current incidence of substance use disorders. Items are rated on a dichotomous Yes/No scale and follow psychiatric guidelines of the DSM-5.

    Time frame: 4 months post release

Secondary outcomes

  1. Recidivism

    Number of days to reincarceration.

    Time frame: 1 year post release

  2. Recidivism

    Number of days to reincarceration.

    Time frame: 2 year post release

  3. Recidivism

    Number of days to reincarceration.

    Time frame: 3 year post release

Other outcomes

  1. Depressive Symptoms

    Depressive symptoms marked by dysphoric mood, inactivity, lack of interest, insomnia, feelings of worthlessness, diminished ability to think, and thoughts of suicide. Depressive symptoms will be measured using the Brief Symptom Inventory, a 53-items with a 6 question sub-scale of depressive symptoms were a respondent characterizes the intensity of distress (0 ="not at all" to 4="extremely").The higher score the more depressive symptoms.

    Time frame: 8 months post release

  2. Anxiety Symptoms

    Anxiety symptoms identified as apprehension or fear of impending actual or imagined danger, vulnerability, or uncertainty. Anxiety Symptoms will be measured using the Brief Symptom Inventory is a 53-items with a 6 question sub-scale of anxiety symptoms were a respondent characterizes the intensity of distress (0 ="not at all" to 4="extremely").The higher score the more symptoms of anxiety.

    Time frame: 8 months post release

  3. Incidence of Substance Use Disorder

    A pathological pattern of impairment related to the overuse of, or dependence on, psychoactive drugs, prescription medications, or other substances. A 9-item substance use disorder subscale of the MINI assesses current incidence of substance use disorders. Items are rated on a dichotomous Yes/No scale and follow psychiatric guidelines of the DSM-5.

    Time frame: 8 months post release

  4. Coping Self-Efficacy Scale

    Utilizing the Coping Self-Efficacy Scale (CSES) to assess coping self-efficacy. The CSES is an 26-item self-report tool that asks respondents to indicate if they feel they can do accomplish 26 specific things if when they are having problems. Responses are based on an 11-point Likert scale (0 = "Cannot do at all" to 10 = "Certain can do"). The CSES provides subscale scores on dimensions of problem-focused coping, stopping unpleasant emotions and thoughts, and social support as well as a total coping self-efficacy score that is calculated based on a sum of all items. Problem focused subscale scores range from 0 to 60, emotion-focused subscale scores range from 0 to 40, and social support subscale scores range from 0 to 30. The total coping self-efficacy score ranges from 0 to 260. Higher scores indicate higher levels of coping self-efficacy.

    Time frame: 4 months post release

  5. Coping Self-efficacy

    he CSES is an 26-item self-report tool that asks respondents to indicate if they feel they can do accomplish 26 specific things if when they are having problems. Responses are based on an 11-point Likert scale (0 = "Cannot do at all" to 10 = "Certain can do"). The CSES provides subscale scores on dimensions of problem-focused coping, stopping unpleasant emotions and thoughts, and social support as well as a total coping self-efficacy score that is calculated based on a sum of all items. Problem focused subscale scores range from 0 to 60, emotion-focused subscale scores range from 0 to 40, and social support subscale scores range from 0 to 30. The total coping self-efficacy score ranges from 0 to 260. Higher scores indicate higher levels of coping self-efficacy.

    Time frame: 8 months post release

  6. Barratt Impulsivity Scale

    Utilizing the Barratt Impulsivity Scale (BIS) to assess general impulsiveness on six first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and three second-order factors (attentional, motor, and non-planning impulsiveness). The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Participants select a number on the following scale: 1 if you rarely or never act or think that way, 2 if you occasionally think that way, 3 if you often think that way, or 4 if you almost or always think that way. Scores range from 30 to 120. A higher score indicates greater impulsivity.

    Time frame: 4 months post release

  7. Barratt Impulsivity Scale

    Utilizing the Barratt Impulsivity Scale (BIS) to assess general impulsiveness on six first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and three second-order factors (attentional, motor, and non-planning impulsiveness). The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Participants select a number on the following scale: 1 if you rarely or never act or think that way, 2 if you occasionally think that way, 3 if you often think that way, or 4 if you almost or always think that way. Scores range from 30 to 120. A higher score indicates greater impulsivity.

    Time frame: 8 months post release

  8. Ryff Psychological Wellbeing Index

    Utilizing the Ryff Psychological Wellbeing Index to assess participant wellbeing. The Ryff is an 18-item self-report tool that asks respondents to indicate how strongly they agree or disagree with 18 statements. Responses are based on a seven-point Likert scale (1 = "strongly agree" to 7 = "strongly disagree"). The Ryff provides subscale scores on dimensions of autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance as well as a global wellbeing index that is calculated based on a sum of all items. Subscale scores range from 3 to 21 and the global wellbeing scores range from 18 to 126. Higher scores indicate higher levels of wellbeing.

    Time frame: 4 months post release

  9. Ryff Psychological Wellbeing Index

    Utilizing the Ryff Psychological Wellbeing Index to assess participant wellbeing. The Ryff is an 18-item self-report tool that asks respondents to indicate how strongly they agree or disagree with 18 statements. Responses are based on a seven-point Likert scale (1 = "strongly agree" to 7 = "strongly disagree"). The Ryff provides subscale scores on dimensions of autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance as well as a global wellbeing index that is calculated based on a sum of all items. Subscale scores range from 3 to 21 and the global wellbeing scores range from 18 to 126. Higher scores indicate higher levels of wellbeing.

    Time frame: 8 months post release

07

Results

Posted Oct 29, 2025
Limitations and caveats
The primary limitation is that there is a relatively small percentage of subjects in the treatment group that completed treatment, although this is a common limitation is reentry work.

Participant flow

Participant flow — Overall Study
MilestoneComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Started196207
Completed28179
Not completed16828

Outcome measures

PrimaryHousing Stability

Stable housing was defined as living in one's own room, apartment, or house, or with family, with an expected duration of residence of 4 months or more, or tenancy rights. A 10- item measure will assess housing stability.

Time frame:
4 months post release
Reported as:
Count of participants · Participants
Housing Stability
ParticipantsTreatment GroupControl Group
Stable Housing1765
Not Housing Stable723
Non-Responsive172119
PrimaryHousing Stability

Stable housing was defined as living in one's own room, apartment, or house, or with family, with an expected duration of residence of 4 months or more, or tenancy rights. A 10- item measure will assess housing stability.

Time frame:
8 months post release
Reported as:
Count of participants · Participants
Housing Stability
ParticipantsTreatment GroupControl Group
Stable1860
Not Housing Stable829
Non-responsive170118
PrimaryEmployment Stability

Employment Stability is measure on a continuum, based on the number of jobs held in the last 4 months and number of days worked at each Employment. The employment must be for at least 15 hours a week. A 10-item measure will assess employment stability

Time frame:
4 months post release
Reported as:
Count of participants · Participants
Employment Stability
ParticipantsComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Employed1667
Not Employed718
Non-Responsive173122
PrimaryEmployment Stability

Employment Stability is based on the number of jobs held in the last 4 months and number of days worked at each Employment. The employment must be for at least 15 hours a week. A 10-item measure will assess employment stability

Time frame:
8 months post release
Reported as:
Count of participants · Participants
Employment Stability
ParticipantsComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Employed2269
Not Employed418
Non-Responsive170120
PrimaryBrief Symptom Inventory

Utilizing the Brief Symptom Inventory (BSI) to assess depression and anxiety symptoms in participants. The BSI is a 53-item self-report screening tool that asks respondents to rate their level of psychological distress over the past seven days based on a five-point Likert scale (0 = "not at all" to 5 = "extremely"). The BSI provides subscale scores on dimensions of somatization, depression, and anxiety as well as a Global Severity Index (GSI) that is calculated based on a sum of all items. Subscale scores range from 0 to 4. Higher scores on the BSI indicate higher levels of symptomology.

Time frame:
4 months post release
Reported as:
Mean · units on a scale
Brief Symptom Inventory
units on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Brief Symptom Inventory.451 ± .804.536 ± .813
PrimaryBrief Symptom Inventory

Utilizing the Brief Symptom Inventory (BSI) to assess depression and anxiety symptoms in participants. The BSI is a 53-item self-report screening tool that asks respondents to rate their level of psychological distress over the past seven days based on a five-point Likert scale (0 = "not at all" to 5 = "extremely"). The BSI provides subscale scores on dimensions of somatization, depression, and anxiety as well as a Global Severity Index (GSI) that is calculated based on a sum of all items. Subscale scores range from 0 to 4. Higher scores on the BSI indicate higher levels of symptomology.

Time frame:
8 months post release
Reported as:
Mean · units on a scale
Brief Symptom Inventory
units on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Brief Symptom Inventory.618 ± .932.553 ± .789
PrimaryMini International Neuropsychiatric Interview

Utilizing the 9-item substance use disorder subscale of the MINI International Neuropsychiatric Interview (MINI) to assess current incidence of substance use disorders. Items are rated on a dichotomous Yes/No scale and follow psychiatric guidelines of the DSM-5.

Time frame:
4 months post release
Reported as:
Count of participants · Participants
Mini International Neuropsychiatric Interview
ParticipantsComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Substance Use Disorder822
No Substance Use Disorder2167
SecondaryRecidivism

Number of days to reincarceration.

Time frame:
1 year post release
Reported as:
Mean · mean number of days to reincarceration
Recidivism
mean number of days to reincarcerationComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Recidivism209.5 ± 103.4169.4 ± 107.3
SecondaryRecidivism

Number of days to reincarceration.

Time frame:
2 year post release
Reported as:
Mean · Mean number of days to reincarceration
Recidivism
Mean number of days to reincarcerationComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Recidivism278.8 ± 165.0280.4 ± 183.6
SecondaryRecidivism

Number of days to reincarceration.

Time frame:
3 year post release
Reported as:
Mean · Mean number of days to reincarceration
Recidivism
Mean number of days to reincarcerationComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Recidivism369.7 ± 275.8357.4 ± 273.7
Other pre-specifiedDepressive Symptoms

Depressive symptoms marked by dysphoric mood, inactivity, lack of interest, insomnia, feelings of worthlessness, diminished ability to think, and thoughts of suicide. Depressive symptoms will be measured using the Brief Symptom Inventory, a 53-items with a 6 question sub-scale of depressive symptoms were a respondent characterizes the intensity of distress (0 ="not at all" to 4="extremely").The higher score the more depressive symptoms.

Time frame:
8 months post release
Reported as:
Mean · score on a scale
Depressive Symptoms
score on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Depressive Symptoms.730 ± .964.440 ± .670
Other pre-specifiedAnxiety Symptoms

Anxiety symptoms identified as apprehension or fear of impending actual or imagined danger, vulnerability, or uncertainty. Anxiety Symptoms will be measured using the Brief Symptom Inventory is a 53-items with a 6 question sub-scale of anxiety symptoms were a respondent characterizes the intensity of distress (0 ="not at all" to 4="extremely").The higher score the more symptoms of anxiety.

Time frame:
8 months post release
Reported as:
Mean · units on a scale
Anxiety Symptoms
units on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Anxiety Symptoms.60 ± 1.15.574 ± .812
Other pre-specifiedIncidence of Substance Use Disorder

A pathological pattern of impairment related to the overuse of, or dependence on, psychoactive drugs, prescription medications, or other substances. A 9-item substance use disorder subscale of the MINI assesses current incidence of substance use disorders. Items are rated on a dichotomous Yes/No scale and follow psychiatric guidelines of the DSM-5.

Time frame:
8 months post release
Reported as:
Count of participants · Participants
Incidence of Substance Use Disorder
ParticipantsComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Substance Use Disorder923
No Substance Use Disorder2067
Other pre-specifiedCoping Self-Efficacy Scale

Utilizing the Coping Self-Efficacy Scale (CSES) to assess coping self-efficacy. The CSES is an 26-item self-report tool that asks respondents to indicate if they feel they can do accomplish 26 specific things if when they are having problems. Responses are based on an 11-point Likert scale (0 = "Cannot do at all" to 10 = "Certain can do"). The CSES provides subscale scores on dimensions of problem-focused coping, stopping unpleasant emotions and thoughts, and social support as well as a total coping self-efficacy score that is calculated based on a sum of all items. Problem focused subscale scores range from 0 to 60, emotion-focused subscale scores range from 0 to 40, and social support subscale scores range from 0 to 30. The total coping self-efficacy score ranges from 0 to 260. Higher scores indicate higher levels of coping self-efficacy.

Time frame:
4 months post release
Reported as:
Mean · score on a scale
Coping Self-Efficacy Scale
score on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Using Problem-Focused Coping45.58 ± 8.4343.52 ± 13.45
Stop Unpleasant emotions and thoughts29.1667 ± 5.7533929.4091 ± 9.03205
Get Support From Friends and Family20.1250 ± 5.4717720.6818 ± 7.89812
Other pre-specifiedCoping Self-efficacy

he CSES is an 26-item self-report tool that asks respondents to indicate if they feel they can do accomplish 26 specific things if when they are having problems. Responses are based on an 11-point Likert scale (0 = "Cannot do at all" to 10 = "Certain can do"). The CSES provides subscale scores on dimensions of problem-focused coping, stopping unpleasant emotions and thoughts, and social support as well as a total coping self-efficacy score that is calculated based on a sum of all items. Problem focused subscale scores range from 0 to 60, emotion-focused subscale scores range from 0 to 40, and social support subscale scores range from 0 to 30. The total coping self-efficacy score ranges from 0 to 260. Higher scores indicate higher levels of coping self-efficacy.

Time frame:
8 months post release
Reported as:
Mean · score on a scale
Coping Self-efficacy
score on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Using Problem-Focused Coping48.23 ± 10.0344.93 ± 10.16
Stop Unpleasant Emotions and Thoughts30.3462 ± 8.0147029.0449 ± 8.76967
Get Support From Friends and Family18.3846 ± 7.4623219.8764 ± 7.20767
Other pre-specifiedBarratt Impulsivity Scale

Utilizing the Barratt Impulsivity Scale (BIS) to assess general impulsiveness on six first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and three second-order factors (attentional, motor, and non-planning impulsiveness). The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Participants select a number on the following scale: 1 if you rarely or never act or think that way, 2 if you occasionally think that way, 3 if you often think that way, or 4 if you almost or always think that way. Scores range from 30 to 120. A higher score indicates greater impulsivity.

Time frame:
4 months post release
Reported as:
Mean · score on a scale
Barratt Impulsivity Scale
score on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Barratt Impulsivity Scale61.63 ± 8.4961.63 ± 11.66
Other pre-specifiedBarratt Impulsivity Scale

Utilizing the Barratt Impulsivity Scale (BIS) to assess general impulsiveness on six first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and three second-order factors (attentional, motor, and non-planning impulsiveness). The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Participants select a number on the following scale: 1 if you rarely or never act or think that way, 2 if you occasionally think that way, 3 if you often think that way, or 4 if you almost or always think that way. Scores range from 30 to 120. A higher score indicates greater impulsivity.

Time frame:
8 months post release
Reported as:
Mean · score on a scale
Barratt Impulsivity Scale
score on a scaleComprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)
Barratt Impulsivity Scale59.96 ± 15.8361.48 ± 12.93
Other pre-specifiedRyff Psychological Wellbeing Index

Utilizing the Ryff Psychological Wellbeing Index to assess participant wellbeing. The Ryff is an 18-item self-report tool that asks respondents to indicate how strongly they agree or disagree with 18 statements. Responses are based on a seven-point Likert scale (1 = "strongly agree" to 7 = "strongly disagree"). The Ryff provides subscale scores on dimensions of autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance as well as a global wellbeing index that is calculated based on a sum of all items. Subscale scores range from 3 to 21 and the global wellbeing scores range from 18 to 126. Higher scores indicate higher levels of wellbeing.

Time frame:
4 months post release
Reported as:
Mean · score on a scale
Ryff Psychological Wellbeing Index
score on a scaleTreatment GroupControl Group
Autonomy35.9538 ± 3.8502333.0000 ± 4.77396
Environmental Mastery32.3333 ± 4.5460631.0795 ± 5.69174
Personal Growth33.7917 ± 4.5490533.2386 ± 4.39695
Positive Relations to Others32.3043 ± 3.4828831.6782 ± 6.16912
Purpose in Life35.2500 ± 3.5783233.6705 ± 5.10065
Self-Acceptance32.5000 ± 3.4007730.2529 ± 5.43721
Other pre-specifiedRyff Psychological Wellbeing Index

Utilizing the Ryff Psychological Wellbeing Index to assess participant wellbeing. The Ryff is an 18-item self-report tool that asks respondents to indicate how strongly they agree or disagree with 18 statements. Responses are based on a seven-point Likert scale (1 = "strongly agree" to 7 = "strongly disagree"). The Ryff provides subscale scores on dimensions of autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance as well as a global wellbeing index that is calculated based on a sum of all items. Subscale scores range from 3 to 21 and the global wellbeing scores range from 18 to 126. Higher scores indicate higher levels of wellbeing.

Time frame:
8 months post release
Reported as:
Mean · score on a scale
Ryff Psychological Wellbeing Index
score on a scaleTreatment GroupControl Group
Autonomy34.6538 ± 5.3810234.2414 ± 5.11488
Environmental Mastery30.1154 ± 7.6750331.1477 ± 6.34368
Personal Growth34.8077 ± 4.7330334.0909 ± 5.52244
Positive Relations to Others31.2400 ± 6.5146032.0568 ± 5.87486
Purpose in Life32.7692 ± 6.4826433.5909 ± 5.24708
Self-Acceptance31.6800 ± 67990230.5698 ± 6.69599

Adverse events

Collected over 1 year, 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group0/196 (0%)0/196 (0%)0/196 (0%)
Control Group0/207 (0%)0/207 (0%)0/207 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
Mean28.07 ± 4.70328.27 ± 4.66428.17 ± 4.68
Sex: Female, Male
Sex: Female, Male(Participants)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
Female000
Male196207403
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
Hispanic or Latino6915
Not Hispanic or Latino190197387
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
American Indian or Alaska Native123
Asian101
Native Hawaiian or Other Pacific Islander022
Black or African American125120245
White5364117
More than one race131932
Unknown or Not Reported303
Region of Enrollment
Region of Enrollment(Participants)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
United States196207403
BSI: Depression
BSI: Depression(units on a scale)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
Mean.265 ± .502.304 ± .538.285 ± .521
BSI: Anxiety
BSI: Anxiety(units on a scale)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
Mean.310 ± .554.370 ± .574.340 ± .564
Barratt Impulsivity Scale
Barratt Impulsivity Scale(units on a scale)Comprehensive Trauma-Based Reentry ProgramTreatment as Usual (TAU)Total
Mean63.45 ± 9.1163.27 ± 9.7963.36 ± 9.46

10 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Institute for Justice Research and Development
    Tallahassee, Florida 32310, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data sharing will be considered for researchers and students, using the IJRD data sharing agreement. Data will be uploaded at the conclusion of the research to the National Archive of Criminal Justice Data, as required by the National Institute of Justice. Contact IJRD for additional information.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be accessible for at least 6 years after the primary analyses have been published.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2023, 27 months.

Results were first posted in Oct 2025, 2 years 4 months after primary completion.

Of 25 interventional studies with no phase under Stress Disorders, Traumatic, Acute, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Mar 8, 2021
StartActual
Feb 9, 2021
Primary completionActual
May 30, 2023
CompletionActual
Jun 30, 2024
Results first posted
Oct 29, 2025
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04785677
Collaborators
U.S. Department of Justice
Responsible party
Stephen Tripodi (Professor;, Florida State University) — Principal investigator
First posted
Mar 8, 2021
Start date
Feb 9, 2021
Primary completion
May 30, 2023
Completion
Jun 30, 2024
Results posted
Oct 29, 2025
Last update
Aug 28, 2026

Study contacts

Carrie Pettus-Davis, PhD
principal investigator · Florida State University College of Social Work, Institute of Justice Research & Development
Stephen Tripodi, PhD
principal investigator · Florida State University College of Social Work, Institute of Justice Research & Development
Tanya Renn, PhD
principal investigator · Florida State University College of Social Work, Institute of Justice Research & Development

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion